Thomas Triomphe: A few more words on flu. So, I’m not going to help you, Richard, to give 2023 flu guidance quite yet. But what I can tell you is that the situation is a bit contrasted in between the . So I think in flu, what we’re seeing in the U.S. is low this year, I would say, but which we expect to increase in the coming years. I would say the fundamentals and the trend is looking good. But again, flu is a progressive uptake year-on-year. It’s way too early to know. You know very well that the current this year is also due to vaccinator’s fatigue, I would say, following the COVID-19 situation. So I remain cautious there. Again, why I think it’s very important is that we have the right assets. You saw the growth of our differentiated flu portfolio, meaning that the impact was much more on the standard flu product.
And as you’ve seen, for example, on recently published results from one of our flu competitors, they had a minus 4% annual flu between 2023 full year and 2022 full year — 2022, sorry, and 2021 full year. You see that on the contrary, thanks to our portfolio, we have a growth in 2022, showing the strength — and the strength of our strategy. So, more than 10 years of data Fluzone high dose and experienced commercial organization, we believe we have the right assets. Let’s wait for the pre-booking. Let’s make sure we know a bit more about the season and the completion of the vaccines, in Q1 we will share more.
Paul Hudson: Yes, as normal. So, thank you for that. Julie, switch update?
Julie Van Ongevalle: Unfortunately, we don’t really have an update. We continue to work with the FDA on the OTC approval for Cialis in the U.S. and we’re advancing on the execution of our strategy to lift the clinical hold including generating the necessary data that was requested. There’s also no update for — on timing for Tamiflu as we continue to incorporate FDA’s most recent feedback into our development program for ’23. And as you all know, the current flu season, which continues to evolve is very dynamic, and we believe really underscores the importance of getting vaccinated, of course, but also the importance of quick widespread consumer access to medication like Tamiflu. So it is important, not just for Sanofi, but for public health, so we continue.
Paul Hudson: So, thank you, Julie. It’s good to get that question actually and the last couple of questions around consumer. Let’s just be really clear. We’re running a great consumer business. It’s growing fast, faster than the market. We have launches to come. Exciting things to do, switches, I think, represent over €1 billion in additional sales between them at peak, and it’s a fast peak, as you know, in Consumer. Again, I wouldn’t listen to gossip. Really spending time just making sure we have the best consumer business and so, that you can compare it to others. And you can see why we’re doing a great job. Thank you to the Executive Committee. Thanks to everybody that dialed in and gave us time. We appreciate it. Look forward to connecting with you soon. We’re well underway. We’re looking forward to 2023. And yes, we’ll look forward to seeing you at certain points on the counter.
Operator: Thank you.
